These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 30297439)

  • 1. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
    Matthews A; Stanway S; Farmer RE; Strongman H; Thomas S; Lyon AR; Smeeth L; Bhaskaran K
    BMJ; 2018 Oct; 363():k3845. PubMed ID: 30297439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
    Yu Q; Xu Y; Yu E; Zheng Z
    J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Disease After Aromatase Inhibitor Use.
    Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
    JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Xu X; Chlebowski RT; Shi J; Barac A; Haque R
    Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
    Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
    Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
    Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
    Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis.
    Yoo JJ; Jung EA; Kim Z; Kim BY
    Curr Oncol; 2023 Feb; 30(2):1831-1843. PubMed ID: 36826103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.
    Chlebowski RT; Haque R; Hedlin H; Col N; Paskett E; Manson JE; Kubo JT; Johnson KC; Wactawski-Wende J; Pan K; Anderson G
    Breast Cancer Res Treat; 2015 Dec; 154(3):609-16. PubMed ID: 26602222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Khosrow-Khavar F; Filion KB; Al-Qurashi S; Torabi N; Bouganim N; Suissa S; Azoulay L
    Ann Oncol; 2017 Mar; 28(3):487-496. PubMed ID: 27998966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
    Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea.
    Kim JE; Choi J; Park J; Han W; Kang D; Choi JY
    J Am Heart Assoc; 2022 Oct; 11(20):e026743. PubMed ID: 36250658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S; Hickey M; Chin J; Su HI
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
    Reinhorn D; Yerushalmi R; Moore A; Desnoyers A; Saleh RR; Amir E; Goldvaser H
    Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.